legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

# MARSEILLE, France, February 21, 2024

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the upcoming investor conference, detailed below.

## Leerink Partners Global Biopharma Conference 2024
Event Date: March 11-13, 2024, Miami, Florida

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.

InnateÔÇÖs portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET┬« multi-specific NK cell engagers to address multiple tumor types.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on [Twitter](https://twitter.com/InnatePharma) and LinkedIn.

## Information about Innate Pharma shares

ISIN code
Ticker code
LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29

## Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the CompanyÔÇÖs commercialization efforts and the CompanyÔÇÖs continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website [AMF website](http://www.amf-france.org) or on Innate PharmaÔÇÖs website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the CompanyÔÇÖs Annual Report on Form 20-F for the year ended December 31, 2022, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

View source version on businesswire.com: [Business Wire](https://www.businesswire.com/news/home/20240220117014/en/)

## Contacts

For additional information, please contact:

**Investors**
Innate Pharma
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
[email protected]

**Media Relations**
NewCap
Arthur Rouill├®
Tel.: +33 (0)1 44 71 00 15
[email protected]

Innate Pharma is a global biotechnology company with a regulatory compliance team dedicated to ensuring legal accuracy in all documentation. By using AI legalese decoder, Innate Pharma’s regulatory team can effectively and efficiently review legal documents, contracts, and compliance materials to ensure they are free from errors, ambiguities, and inconsistencies. This advanced tool can help the company save time and resources in legal document review and ensure that all communication with regulatory bodies and investors is clear and legally sound.

legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Reference link